8-K - Immunic, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Immunic, Inc. appointed Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years of experience, to its Board of Directors effective March 27, 2026, expanding the Board to nine members.

Key Takeaways

1Jon Congleton appointed as Class II director effective March 27, 2026, with term lasting until the 2028 annual meeting.

2Mr. Congleton will serve as Chair of the Compensation Committee of the Board.

3Board size increased from eight to nine directors in connection with the appointment.

4Mr. Congleton received an inaugural grant of options to purchase 500,000 shares vesting monthly over three years.

5The option award is subject to shareholder approval of an increase to shares reserved under the 2019 Omnibus Equity Incentive Plan.

Current Report Details

Event Type

Management Change

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** On Marc

Management Change

7.01

and in Exhibit 99.1 shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act, or the Exchange Act, whether ma

Regulation Fd

9.01

. Financial Statements and Exhibits.** ** ** | Exhibit No. | Description of Exhibit | |---|---| | 99.1 | Press release, dated March 31, 2026 | | 104 | Cover Pag

Exhibits Only

Source Document

Executive & Director Changes

Jon Congleton

Class II Director and Chair of the Compensation Committee

Appointed

Effective: 2026-03-27

Board expansion and strengthening with seasoned biopharmaceutical executive.

Exhibits (2)

8-K

Exhibit

99.1

Exhibit